China’s C-List and Beyond: Group Insurance, Provider Uptake, and Commercial Payment Strategies
A practical implementation deep-dive with Professor Wanyan on China’s C-List and broader commercial payment landscape — covering group health insurance, provider uptake, cross-stakeholder bottlenecks, orphan therapy coverage, TPAs, and scalable payment strategy.
China’s C-List in Practice: Early Huiminbao Integration Signals
A practical discussion with Professor Wanyan on Huiminbao benefit design changes, regional adoption differences, local negotiation dynamics, and what early implementation may signal for broader commercial insurance integration.
China’s C-List: Behind-the-Scenes Negotiation Dynamics
A practical implementation deep-dive into China’s 2025 C-List negotiation process with Professor Wanyan — covering insurer participation, NHSA’s role, selection criteria, pricing negotiation, and future commercial insurance formulary trends.
China’s 2026 Dual-List Draft Workplan: Earlier Innovation Access, Tighter Lifecycle Pricing Discipline
China’s 2026 NRDL draft workplan signals a more integrated, lifecycle-oriented reimbursement framework: earlier access for innovative therapies, closer regulatory–reimbursement alignment anchored in RWE, and tighter pricing discipline for mature and me-too products.
From Reference Tool to Operating Model: A Roadmap for China’s C-List
China’s C-List establishes a national reference for innovative drugs outside the NRDL—but not yet a payment system. Its impact will hinge on whether insurers and regulators can turn policy intent into a workable, risk-sustainable commercial coverage model.
NFRA’s Guiding Opinions: What They Mean for China’s Multi-Level Coverage Framework
NFRA’s latest Guiding Opinions signal a shift toward a more innovation-friendly commercial health insurance ecosystem. The article unpacks five key policy themes with critical implications for the C-List rollout and the building of China’s multi-level coverage framework.
▶️Making the C-List Work: Lessons and Next Steps for Pharma
The final Health Policy and Financing Panel wrapped up the C-List Masterclass with reflections, insurer perspectives, global case studies, and Q&A—highlighting how manufacturers can turn C-List inclusion into a true springboard for coverage.
▶️Frontline Perspectives: Realities and the Road Ahead for Commercial Health Insurance in China
Two senior commercial insurance leaders share candid views on China’s evolving market—what’s working, where integration lags, and if the new commercial innovative drug list could help close gaps and drive future growth.
▶️Fudan’s Wanyan Ruiyun on Huiminbao and the C-List: From Central Negotiation to Market Uptake and Insurance Innovation
Fudan expert shares insights on China’s first national negotiation for the commercial drug list—and its potential to reshape Huiminbao, influence drug pricing, accelerate insurance innovation, and transform drug distribution systems nationwide.
▶️Navigating China’s Multi-Level Coverage Framework: Insights from the C-List Strategy Panel
Industry leaders unpack China’s evolving multi-level coverage system—what the dual-list means for pricing risk, NRDL vs. commercial access, and long-term strategy in the C-List era.
